B. Szafran,1,2 T. Chwiej,1,2 F. M. Peeters,1 S. Bednarek,2 J. Adamowski,2 and B. Partoens1 1Departement Fysica, Universiteit Antwerpen (Campus Drie Eiken), Universiteitsplein 1, B-2610 Antwerpen, Belgium 2Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, al. Mickiewicza 30, 30-059 Kraków, Poland sReceived 27 July 2004; revised manuscript received 15 Nove...

Karol Życzkowski,* Paweł Horodecki, Michał Horodecki, and Ryszard Horodecki Centrum Fizyki Teoretycznej PAN, Al. Lotników 32/46, 02-668 Warszawa, Poland Instytut Fizyki im. Smoluchowskiego, Uniwersytet Jagielloński, ul. W” . Reymonta 4, 30-059 Kraków, Poland Wydział Fizyki Technicznej i Matematyki Stosowanej, Politechnika Gdańska, ul. G. Narutowicza 11/12, 80-952 Gdańsk, Poland Instytut Fizyki ...

BACKGROUND AND PURPOSE Numerous neuroprotective agents have proven effective in animal stroke studies, but every drug has failed to achieve its primary outcome when brought forward to clinical trials. We analyzed the quality and adequacy of animal studies supporting the efficacy of NXY-059 and other neuroprotective agents that are currently being investigated in phase II/III trials. METHODS W...